B+
Bull case
0%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
GRFS
GrifolsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Sustained immunoglobulin growth, improved cash generation and a favorable SPARTA readout could support a higher valuation. Grifols reported H1 immunoglobulin growth of 12.8% at constant currency.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
H1 leverage of 4.2x leaves the equity sensitive to weaker cash conversion or slower deleveraging. [#IR-2026-07-28] Grifols H1 results
Momentum
71
Value
66
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.80 · Bull $9.50 · Bear $5.50Analysis 2026-10-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $11.30
Why
Momentum71 · Δ7d +13.0
Value66 · Δ7d -0.3
Sentiment51 · Δ7d +1.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.3.
Contradictions & invalidation
- • H1 leverage of 4.2x leaves the equity sensitive to weaker cash conversion or slower deleveraging. [#IR-2026-07-28] Grifols H1 results
- • H2 immunoglobulin growth, Biotest improvement and plasma-sourcing efficiencies may not translate into sustained margins and free cash flow. [#IR-2026-07-28] Grifols H1 results
- • At 4.2x H1 leverage, weaker cash conversion or an unfavorable SPARTA readout could outweigh operating progress.
Catalyst clock
2026-12-31
SPARTA Phase 3 topline readout
Lead driver: Value · See fundamentals
Momentum
71
8% active weight
Current posture
7d trendSoftening
Δ7d
+13.0
Δ21d
+39.9
Value
66
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-1.0
Sentiment
51
45% active weight
Current posture
7d trendImproving
Δ7d
+1.4
Δ21d
-
Why this grade
Composite grade B. Momentum 71.4 / Value 65.9 / Sentiment 51.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-17. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$7.80
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$7.05B
Beta
1.57
Shares Out
258.22M
P/E (TTM)
20.7
P/S (TTM)
0.92
P/FCF (TTM)
9.90
Rev YoY
+1.7%
EPS YoY
+34.8%
Gross Margin
+37.0%
Op Margin
+16.2%
Net Debt
$9.3B
Current Ratio
2.37
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data